Pharmaceutical Formulations (Medium Scale) Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

Pharmaceutical formulations (medium scale) sits under India's strictest regulatory regime (CDSCO at the centre, state Drug Controllers, plus WHO-GMP and Schedule M). For ₹9.3 crore - ₹112 crore CapEx this DPR captures:

• NABL accreditation for QC lab, BSL-2/BSL-3 containment certification where applicable
• Bio-medical waste authorisation under BMW Rules 2016
• PLI Bulk Drugs (₹15,000 cr) or PLI Medical Devices (₹3,420 cr) participation
• NABH / NABL accreditation if the project includes a clinical or diagnostic arm
• Manufacturing licence under the Drugs and Cosmetics Act 1940 (Form 25/28/28A by category)
• CDSCO + State Drug Controller dual approval for new formulations
• WHO-GMP and Schedule M revised standards compliance

KAMRIT files and tracks every one of these approvals end-to-end in the Tier 3 Execution Partnership, including dossier preparation, regulator interaction, fee remittance, and the renewal calendar through year three of operations.

The pharmaceutical formulation segment in India operates within a rapidly expanding global market context. The global pharmaceutical market was estimated at USD 1.83 trillion to USD 2.15 trillion in 2026, expanding at a compound annual growth rate (CAGR) of 6.1 percent to 8.19 percent, while the global drug formulation market alone stood at USD 2.08 trillion in 2026 and is projected to reach USD 3.50 trillion by 2035. India's domestic formulation sales are projected at USD 27.72 billion in 2026, with the overall India pharmaceutical market reaching USD 60.32 billion in 2026 and estimated to grow to USD 79.74 billion by 2031 at a CAGR of 5.74 percent.

The India pharmaceutical manufacturing sector specifically reached USD 20.6 billion in 2025 and is projected to scale to USD 36.5 billion by 2034. Conventional pharmaceutical formulations account for approximately 76.0 percent of the domestic market. Drug Formulations and Biologicals together account for approximately 75 percent of total pharmaceutical exports from India, reflecting the sector's strong export orientation.

The pharmaceutical contract development and manufacturing organization (CDMO) market, a key opportunity area for medium-scale operators, was valued at USD 52.56 billion in 2026 and is projected to reach USD 103.33 billion by 2035. Mid-tier players account for approximately 54 percent of active manufacturing participants within the contract development and manufacturing space. The sector's FY25 exports stood at USD 30.5 billion, while the broader industry turnover reached Rs. 2,25,000 crore (USD 26.26 billion) in FY25.

Project-specific demand drivers

• PLI Bulk Drug and Medical Devices
• US generics export opportunity
• Health insurance penetration rising
• Chronic disease burden growth

The medium-scale pharmaceutical formulations segment is undergoing a significant technological transformation driven by the need for greater efficiency, compliance, and quality assurance. Continuous manufacturing is emerging as a key technological shift, with medium-scale formulation suites transitioning to continuous processing to eliminate downtime between batches and minimize material losses. This transition reduces manufacturing footprint and operational costs, with advanced continuous processes achieving Process Mass Intensity (PMI) values substantially lower than the 25 to 100 range typical of conventional medium-scale pharmaceutical processes.

Manufacturing Execution Systems (MES) are increasingly being adopted, with vendors such as POMS Corporation offering plug-and-play, native out-of-the-box integration solutions that reduce implementation complexity for medium-scale facilities. Quality assurance remains a challenge, as approximately 63 percent of life sciences and pharmaceutical companies continue to rely on manual, paper-based processes for critical production line changeovers, according to Catalyx 2025 data. Further, 70 percent of organizations experience at least one line clearance or cleaning failure within a 12-month period to prevent cross-contamination, while 30 percent report six or more line clearance failures annually, highlighting a significant technology and process gap that presents both a risk and an opportunity for technology upgradation.

The pharmaceutical manufacturing equipment market globally stood at USD 25.14 billion in 2026 and is projected to reach USD 46.21 billion by 2034 at a CAGR of 7.9 percent, reflecting growing capital investment in manufacturing infrastructure.

For a pharmaceutical formulations (medium scale) project at ₹9.3 crore - ₹112 crore CapEx with a 3.2 - 6.0-year payback, the bank-loan-ready Means of Finance KAMRIT recommends is 30-40% promoter equity and 60-70% debt. The primary lender pool for this scale is SBI MSME, Bank of Baroda, HDFC Bank, ICICI Bank, Axis Bank term loans plus working capital facilities. The applicable overlay schemes that materially compress effective cost-of-capital are CGTMSE up to ₹5 cr, PLI sector overlay where eligible, state capital subsidy. The Tier 2 Bankable DPR includes the full vendor-quote-backed CapEx schedule, OpEx model, 5-year revenue projection split by SKU and channel, working-capital cycle, ROI/NPV/IRR, break-even, and sensitivity in three scenarios (base / bull / bear). The model is structured for direct submission to a commercial bank or NBFC credit appraisal team.

The medium-scale pharmaceutical formulations segment faces several material risks that warrant careful consideration. India imports approximately 35 percent of its total API requirements, with approximately 74 percent of those imports sourced from China, creating significant supply chain vulnerability to geopolitical disruptions, trade policy shifts, and price volatility in API markets. Capital requirements for setting up a medium-scale formulation plant range from Rs. 50 crore to Rs. 80 crore (approximately USD 5 million to USD 50 million), representing a substantial barrier to entry and a financial risk in the event of demand fluctuations.

Price regulation remains a persistent headwind: the NPPA placed 928 drugs under price control in 2025, directly compressing gross margins for medium-scale manufacturers of essential medicines. Quality and compliance risks are acute, with 70 percent of organizations experiencing at least one line clearance or cleaning failure in a 12-month period and 30 percent reporting six or more failures annually, indicating that cross-contamination risks could lead to regulatory action, product recalls, and reputational damage. The persistence of paper-based processes in 63 percent of firms signals an operational efficiency gap that exposes operators to human error and non-compliance with evolving cGMP requirements.

While the global pharmaceutical market is growing robustly, the domestic market faces margin compression from price controls, and medium-scale operators may lack the pricing power and diversified portfolios of large-cap peers. Dependence on the USFDA approval pathway for export revenues introduces regulatory risk, as any compliance deficiency at a facility could result in warning letters or import alerts. The sector turnover of Rs. 4.72 lakh crore in FY25, while large, reflects growth deceleration pressures in the domestic market compared to the robust 10.98 percent CAGR projected for the broader market, suggesting medium-scale operators must actively pursue export and CDMO opportunities to sustain growth trajectories.